These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 20211060

  • 1. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ, Wang WX, Lin L, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [Abstract] [Full Text] [Related]

  • 2. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA.
    Cancer Res; 2004 Jun 01; 64(11):3761-6. PubMed ID: 15172981
    [Abstract] [Full Text] [Related]

  • 3. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):679-86. PubMed ID: 19639316
    [Abstract] [Full Text] [Related]

  • 4. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.
    Cancer Chemother Pharmacol; 2017 Oct 01; 80(4):765-775. PubMed ID: 28887583
    [Abstract] [Full Text] [Related]

  • 5. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC.
    Pharmacogenet Genomics; 2006 Jun 01; 16(6):429-38. PubMed ID: 16708051
    [Abstract] [Full Text] [Related]

  • 6. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
    Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, de Braud F.
    Pharmacogenomics J; 2010 Jun 01; 10(3):180-90. PubMed ID: 19901957
    [Abstract] [Full Text] [Related]

  • 7. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H.
    Eur J Cancer; 2015 Nov 01; 51(16):2480-9. PubMed ID: 26254808
    [Abstract] [Full Text] [Related]

  • 8. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group.
    Clin Cancer Res; 2004 Feb 15; 10(4):1318-25. PubMed ID: 14977831
    [Abstract] [Full Text] [Related]

  • 9. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
    Qiu ZQ, Zhao K.
    Asian Pac J Cancer Prev; 2014 Feb 15; 15(17):7303-7. PubMed ID: 25227833
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS, Patel SR.
    J Exp Clin Cancer Res; 2009 Jun 06; 28(1):76. PubMed ID: 19500405
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 06; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 12. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May 06; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

  • 13. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y.
    Respirology; 2008 Jun 06; 13(4):510-7. PubMed ID: 18494946
    [Abstract] [Full Text] [Related]

  • 14. [Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
    Luo Y, Lin C, Zhang XY, Liang X, Fu M, Feng FY.
    Zhonghua Zhong Liu Za Zhi; 2009 Sep 06; 31(9):660-3. PubMed ID: 20021860
    [Abstract] [Full Text] [Related]

  • 15. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
    Dong M, Feng FY, Lin C, Zhang XY, Fu M, Liang X, Zha YY, Lu HY, Wu M.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):323-8. PubMed ID: 15059518
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC.
    Clin Cancer Res; 2008 May 15; 14(10):3083-8. PubMed ID: 18483375
    [Abstract] [Full Text] [Related]

  • 17. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 15; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 18. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.
    Ann Oncol; 2006 Dec 15; 17(12):1818-25. PubMed ID: 16980606
    [Abstract] [Full Text] [Related]

  • 19. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug 15; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 20. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
    Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G.
    N Engl J Med; 2007 Feb 22; 356(8):800-8. PubMed ID: 17314339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.